COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Mar 7, 2022

Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases

Oct 8, 2021

Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine

May 25, 2021

Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University

Sep 1, 2020

Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University

Jun 4, 2020

FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure

For More Press Releases

---